{"filings":[{"id":109792,"accession_number":"0001213900-26-003998","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Estrella Immunopharma receives Nasdaq deficiency notice for failure to hold annual meeting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq letter on Jan 7, 2026, citing non-compliance with Listing Rule 5620(a) for not holding annual meeting.","Company has 45 calendar days to submit a plan to regain compliance.","Expects to convene annual meeting in April 2026 and will consult with Nasdaq on compliance.","No immediate impact on listing or trading of ESLA common stock or ESLAW warrants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":109791,"accession_number":"0001213900-26-001777","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2026-01-06T23:59:59+00:00","items":["1.01","3.02","7.01","9.01"],"status":"ready","headline":"Estrella Immunopharma raises $8.0M in registered direct offering and private placement","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $8.0M from sale of 4,063,290 shares, 1,000,000 pre-funded warrants, and 7,594,935 PIPE common warrants.","Combined unit price of $1.58 per share/warrant; PIPE warrants exercisable at $1.39 for 5 years.","Net proceeds for general corporate purposes and working capital to advance Phase II trial of EB103.","Placement agent Aegis Capital Corp. received a 6% cash fee on gross proceeds."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126329,"accession_number":"0001213900-25-118097","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-12-04T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Estrella advances STARLIGHT-1 to Phase II after DSMB OK; 100% CR in high-dose cohort","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["DSMB recommends Phase II at RP2D after no treatment-related SAEs in Phase I (n=9).","High-dose cohort achieved 100% complete response (CR) rate at Month 1 in evaluable patients.","Phase II expansion will evaluate EB103 in relapsed/refractory B-cell NHL at RP2D.","Majority of Phase I patients were high-risk, including one with CNS lymphoma."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126328,"accession_number":"0001213900-25-107249","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Estrella Immunopharma completes second dose cohort in EB103 trial; 100% CR rate","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["100% complete response (CR) rate at Month 1 in all evaluable patients in second dose cohort of STARLIGHT-1 trial.","All patients are high-risk, including one with CNS lymphoma; no treatment-related serious adverse events reported.","DSMB will review cumulative data to determine Recommended Phase II Dose (RP2D) for expansion phase.","EB103 is a CD19-redirected ARTEMIS T-cell therapy for relapsed/refractory B-cell Non-Hodgkin's Lymphoma (NHL)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143082,"accession_number":"0001213900-25-093197","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-09-29T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Estrella Immunopharma regains Nasdaq compliance on bid price and market value","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Regained compliance with Nasdaq minimum bid price rule (5550(a)(2)) after 10 consecutive days of closing bid ≥ $1.00 (Sept 9-22, 2025).","Regained compliance with Nasdaq minimum market value of listed securities rule (5550(b)(2)) after 17 consecutive days of MV ≥ $35M (Aug 28-Sept 22, 2025).","Both compliance matters are now closed; previously disclosed non-compliance resolved."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143081,"accession_number":"0001213900-25-092471","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-09-26T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Estrella Immunopharma appoints Jia Dengyao to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"medium","bullets":["Board appointed Jia Dengyao as director effective September 22, 2025.","Mr. Jia has not been named to any Board committees as of the filing.","Company entered into standard indemnification agreement with new director.","Appointment adds a new independent voice but no other details provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143080,"accession_number":"0001213900-25-072746","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Estrella Immunopharma receives Nasdaq non-compliance notice for MVLS below $35M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nasdaq notice on Aug 1, 2025 for failing to maintain minimum MVLS of $35M for 30 consecutive business days.","Non-compliance period identified as June 13, 2025 to July 31, 2025.","Company has 180 days, until Jan 28, 2026, to regain compliance with MVLS of $35M+ for 10 consecutive business days.","Also noted non-compliance with alternative listing rules 5550(b)(1) and 5550(b)(3).","No immediate effect on listing; Company will monitor and consider options but cannot assure regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161191,"accession_number":"0001213900-25-051361","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-06-05T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Estrella Immunopharma activates second clinical site for Phase I/II STARLIGHT-1 NHL trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Baylor Research Institute in Dallas, TX now open for patient enrollment in STARLIGHT-1 trial.","Trial evaluates EB103, a CD19-Redirected ARTEMIS T-cell therapy for relapsed/refractory B-cell NHL.","Open-label, dose escalation/expansion Phase I/II study to determine Recommended Phase II Dose in adults ≥18.","CEO Cheng Liu states partnership will accelerate development and increase patient access to EB103."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161190,"accession_number":"0001213900-25-050329","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["1.01","3.02","8.01","9.01"],"status":"ready","headline":"Estrella Immunopharma raises ~$3.35M in PIPE at $1.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 2,233,334 shares at $1.50 each (premium to $1.00 close on May 29, 2025).","Net proceeds to fund Phase I STARLIGHT-1 trial of EB103 CD19-targeted T-cell therapy in NHL.","True-Up provision: additional shares if 12-month closing price below $1.50 (floor $0.20).","Company agreed to file resale registration statement for shares issued in PIPE.","Closing subject to customary conditions; investor support cited as confidence in ARTEMIS platform."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161189,"accession_number":"0001213900-25-048597","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-05-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Estrella Immunopharma doses first patient in STARLIGHT-1 second cohort for EB103 in NHL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in second cohort of Phase I/II STARLIGHT-1 trial evaluating EB103 at higher dose.","No dose-limiting toxicities or treatment-related serious adverse events observed in first cohort.","Complete response reported in first cohort; trial targets advanced B-cell non-Hodgkin's lymphomas.","CEO Cheng Liu highlights potential for HIV-associated and CNS lymphoma patients currently excluded from CAR-T."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161188,"accession_number":"0001213900-25-039261","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-05-02T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Estrella Immunopharma receives Nasdaq bid price deficiency notice; faces potential delisting","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Estrella that common stock failed to maintain $1.00 minimum bid for 30 consecutive days through April 28, 2025.","Company has 180-day compliance period (until October 27, 2025) to regain compliance with Bid Price Rule.","If not compliant by October 27, may seek additional 180-day period if it meets other listing standards.","No immediate effect on listing; common stock and warrants continue trading on Nasdaq under ESLA and ESLAW."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179351,"accession_number":"0001213900-25-015851","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-02-21T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Estrella Immunopharma completes first dose cohort in STARLIGHT-1; DSMB approves second dose","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First cohort enrolled relapsed/refractory B-cell NHL patients who failed multiple prior therapies; no DLTs or SAEs.","DSMB approved escalation to second cohort at 5 million receptor-positive T cells/kg of EB103 therapy.","Preliminary data showed tumor responses in all patients at Month 1; favorable safety profile.","STARLIGHT-1 is an open-label, multi-center 3+3 dose-escalation study to determine RP2D for EB103."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179350,"accession_number":"0001213900-25-015364","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2025-02-20T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Estrella Immunopharma receives Buy rating from D. Boral Capital with $16 price target","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["D. Boral Capital initiates coverage on Estrella (ESLA) with a Buy rating and 12-month price target of $16.00 per share.","Lead candidate EB103, a CD19/CD22-targeted ARTEMIS® T-cell therapy, is in Phase I/II trials for B-cell Non-Hodgkin's Lymphoma.","D. Boral Capital's valuation model assumes 30% probability of success and a 30% discount rate.","D. Boral Capital will also provide investment banking services, creating a potential conflict of interest."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196049,"accession_number":"0001213900-24-109285","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-12-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Estrella Immunopharma regains compliance with both Nasdaq listing requirements","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Regained compliance with Stockholders' Equity Requirement after market value of listed securities exceeded $35M for 10 consecutive days ending Dec 10, 2024.","Regained compliance with Minimum Bid Price Requirement after closing bid price of common stock stayed at $1.00+ for 10 consecutive days ending Dec 10, 2024.","Both Nasdaq deficiency matters are now closed; no further action required."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196048,"accession_number":"0001213900-24-106238","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-12-06T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Estrella Immunopharma extends equity line with White Lion to Dec 2025, adds rapid share purchase mechanism","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Amendment extends existing up-to-$50M stock purchase agreement from Dec 30, 2024 to Dec 30, 2025.","New 'Rapid Purchase' mechanism allows expedited share sales at lowest traded price on notice date.","Rapid purchase limit is the lesser of 20% of average daily trading volume or investment limit divided by highest close over five days.","Standard purchase discount remains 97% (up to $25M) then 98%; rapid purchases use lowest traded price (0% discount).","Company delivers Rapid Purchase Notice by 11:00 a.m. NY time with concurrent DWAC transfer; payment due next business day by 5 p.m."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196047,"accession_number":"0001213900-24-102899","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-11-26T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Estrella Immunopharma changes fiscal year end to Dec 31, transition period Jul-Dec 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board approved fiscal year change from June 30 to December 31 effective November 25, 2024.","Transition period covers July 1, 2024 through December 31, 2024.","Company will file Form 10-KT with audited financials for the transition period."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196046,"accession_number":"0001213900-24-102134","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-11-25T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Estrella Immunopharma receives Nasdaq deficiency notices for low equity and low bid price","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity of $746,286 as of Sep 30, 2024, below Nasdaq's $2.5M minimum.","Has until Jan 3, 2025 to submit a compliance plan; Nasdaq may grant up to 180-day extension.","Separate bid price deficiency: common stock below $1.00 for 30 consecutive business days; cure period until May 19, 2025.","Both deficiencies have no immediate effect on listing, but failure to regain compliance could lead to delisting.","Company evaluating options to regain compliance; no assurance of success."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196045,"accession_number":"0001213900-24-095506","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Estrella Immunopharma enters employment agreement with CEO Cheng Liu; base salary $250,000","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Base salary of $250,000 per year, plus annual cash bonus based on performance metrics set by Compensation Committee.","Severance: 6 months base salary for termination without cause or resignation for good reason; 12 months plus equity acceleration if tied to change in control.","Agreement includes non-disclosure and confidentiality covenants; effective November 1, 2024, at-will employment.","CEO retains ability to hold outside directorships and positions, subject to Board review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196044,"accession_number":"0001213900-24-095507","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K/A","filed_at":"2024-11-07T23:59:59+00:00","items":["1.01","5.02","9.01"],"status":"ready","headline":"Estrella Immunopharma enters consulting agreement with chairperson's company Cofame","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Estrella Immunopharma entered a Consulting Agreement with Cofame Investment Management, owned by Chairperson Hong Zhang, for advisory services up to three days per week.","Cofame receives $55,000 upfront and an annual fee of $220,000; Hong Zhang granted option to purchase 1,000,000 shares under the 2023 Omnibus Incentive Plan.","Option vests 25% on August 1, 2025, with the remaining 75% vesting monthly over 36 months, contingent on continued service.","The Audit Committee reviewed and approved the agreement as a related-party transaction."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212294,"accession_number":"0001213900-24-071174","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-08-20T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Estrella Immunopharma appoints Hong Zhang as Chairperson and Board member","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Hong Zhang appointed Chairperson and director effective Aug 14, 2024; board expands from 5 to 6.","Ms. Zhang brings 25+ years financial and corporate strategy experience; previous Chairman Dr. Cheng Liu remains on board.","Compensation: $5,000/quarter as director + $2,500/quarter as Chairperson; expenses reimbursed.","Company also negotiating consulting agreement with entity owned by Ms. Zhang for Asian strategic initiatives; terms pending approval.","Press release notes dosing of first patient in Phase I/II trial STARLIGHT-1 for EB103 in R/R B-cell NHL."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212293,"accession_number":"0001213900-24-065292","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Estrella Immunopharma doses first patient in Phase I/II trial for EB103 in B-cell NHL","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["First patient dosed in STARLIGHT-1 Phase I/II trial of EB103, an autologous anti-CD19 ARTEMIS T-cell therapy.","Target indication: relapsed/refractory B-cell Non-Hodgkin's Lymphomas (R/R B-cell NHL).","Trial is open-label, dose escalation/expansion to assess safety and determine Recommended Phase II Dose (RP2D).","Principal Investigator: Naseem Esteghamat, M.D., at UC Davis Comprehensive Cancer Center.","Clinical trial identifier on ClinicalTrials.gov: NCT06343311."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212292,"accession_number":"0001213900-24-058085","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-07-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Estrella Immunopharma merges wholly-owned sub Estrella Biopharma into parent","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Merger effective June 30, 2024; Estrella Biopharma ceased to exist, Estrella Immunopharma survives.","No changes to management, board, ownership, charter, or bylaws as a result of the merger.","Merger approved by unanimous written consent of board; intended to simplify corporate structure and streamline financial reporting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231229,"accession_number":"0001213900-24-042444","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-05-13T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Estrella Immunopharma amends clinical trial service agreement with Eureka to clarify termination payment terms","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amendment No. 1 to SOW #001 for EB103 anti-CD19 ARTEMIS® clinical trial clarifies pay-on-termination obligations.","Upon termination, Estrella pays only for achieved milestones, pass-through costs, and third-party commitments before notice.","Eureka must use commercially reasonable efforts to cancel or reduce such third-party commitments.","Amendment effective March 4, 2024; filed on May 13, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.25,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231228,"accession_number":"0001213900-24-031716","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-04-10T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Estrella Immunopharma posts investor presentation; EB103 Phase I expected 1H 2024","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["EB103 (CD19 ARTEMIS) IND cleared Q1 2023; Phase I trial targeted for 1H 2024 in r/r B-cell lymphoma.","IIS study: 6/12 CR (50%), 4/12 PR (33%), ORR 83%; no severe CRS; durable responses up to 23.2 months.","Partnered with Imugene (ASX:IMU) to combine CF33-CD19t oncolytic virus with EB103 for solid tumors.","Pipeline includes EB104 (CD19/CD22 dual-targeting) for lymphoma and EB201 for SLE (preclinical)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249624,"accession_number":"0001213900-24-021186","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-03-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Estrella Immunopharma details $1M share repurchase: open market buys via 10b5-1 plan over 12 months","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board authorized up to $1,000,000 in common stock repurchases (first announced Jan 30, 2024).","Repurchases expected via open market trades at prevailing prices under a Rule 10b5-1 plan.","Company will use existing cash reserves; plan may be modified or terminated based on market conditions.","Expected to occur within the next 12 months."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":249623,"accession_number":"0001213900-24-020566","cik":1844417,"company_name":"Estrella Immunopharma, Inc.","ticker":"ESLA","form_type":"8-K","filed_at":"2024-03-07T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Estrella Immunopharma signs $33M clinical trial SOW with Eureka for EB103 Phase I/II NHL trial","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total fees of $33M for 20-patient Phase I/II trial of EB103 anti-CD19 ARTEMIS T-cell therapy in R/R B-cell NHL.","Initial invoice of $3.5M due upon execution; $1.5M deposit before dosing; $1.375M per patient for 20 patients.","Estimated dosing: 6 patients by end of 2024, 14 more by end of 2025; study close-out by end of 2025.","Eureka Therapeutics, controlling shareholder of Estrella, provides services; includes cooperation for financing compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":49489358.0,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}